Vaginal Atrophy - Drug Pipeline Landscape, 2023

Vaginal Atrophy - Drug Pipeline Landscape, 2023

Vaginal Atrophy is a condition in which vagina gets drier and thinner and inflammation of the Vaginal walls may occur when the body has less estrogen. Vaginal Atrophy in which Vaginal refers to the vagina while Atrophy means wasting away or diminution occurs most often after menopause. For Many women, Vaginal Atrophy not only makes intercourse painful but also leads to distressing urinary symptoms

Vaginal Atrophy most likely experienced by women at the age of 50 years and older in menopause and lack of sexual intercourse, decreased ovarian functioning due to chemotherapy or radiation, immune disorders, nonfluctuating estrogen levels, Oophorectomy (Removal of the Ovaries), Postpartum loss of placental estrogen are the some of the cause of Vaginal Atrophy

Signs and Symptoms of Vaginal Atrophy include thinning of the Vaginal walls and lack of Vaginal moisture (Vaginal dryness), Vaginal burning (Inflammation) and a shortened or narrowed vagina canal discomfort or pain during intercourse and burning during urination more frequent urinary tract infections

Diagnosis of Vaginal atrophy include pelvic exam, urine test and acid balance test.

Lubricants and moisturizers will add moisture and loosen the vagina and also treat dryness. Estrogen therapy often is used to treat symptoms of Vaginal Atrophy.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Vaginal Atrophy treatment such as DARE-VVA1, Intrarosa, Donesta and others. Key players involved in the development of therapies to treat Vaginal Atrophy are Bayer AG, Dara bioscience Inc, Mithra Pharmaceuticals SA and others. Two drugs are under late-stage Phase III clinical trials and one drug are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

In November 2022, Dara Bioscience announced positive topline results from DARE-VVA1 Phase 1/2 clinical study.

Report Highlights

Global Insight Service's, Vaginal Atrophy - Drug Pipeline Landscape, 2023 report provides an overview of the Vaginal Atrophy pipeline drugs. This report covers detailed insights on Postmenopausal Vaginal Atrophy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Postmenopausal Vaginal Atrophy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.